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Abstract
Aims/hypothesis Our aimwas to assess the use of continuous subcutaneous insulin infusion (CSII) in people with type 1 diabetes
in Scotland and its association with glycaemic control, as measured by HbA1c levels, frequency of diabetic ketoacidosis (DKA)
and severe hospitalised hypoglycaemia (SHH), overall and stratified by baseline HbA1c.
Methods We included 4684 individuals with type 1 diabetes from the national Scottish register, who commenced CSII between
2004 and 2019. We presented crude within-person differences from baseline HbA1c over time since initiation, crude DKA and
SHH event-rates pre-/post-CSII exposure. We then used mixed models to assess the significance of CSII exposure, taking into
account: (1) the diffuse nature of the intervention (i.e. structured education often precedes initiation); (2) repeated within-person
measurements; and (3) background time-trends occurring pre-intervention.
Results HbA1c decreased after CSII initiation, with a median within-person change of −5.5 mmol/mol (IQR −12.0, 0.0) (−0.5% [IQR
−1.1, 0.0]). Within-person changes were most substantial in those with the highest baseline HbA1c, with median −21.0 mmol/mol
(−30.0,−11.0) (−1.9%[−2.7,−1.0]) change in thosewithabaseline>84mmol/mol (9.8%)within ayearof exposure, thatwas sustained:
−19.0mmol/mol (−27.6,−6.5) (−1.7% [−2.5,−0.6]) at≥5years. Statistical significance andmagnitude of changewere supported by the
mixedmodels results.ThecrudeDKAevent-ratewassignificantly lower inpost-CSIIperson-timecomparedwithpre-CSIIperson-time:
49.6 events (95% CI 46.3, 53.1) per 1000 person-years vs 67.9 (64.1, 71.9); rate ratio from Bayesian mixed models adjusting for pre-
exposure trend: 0.61 (95%credible interval [CrI] 0.47, 0.77; posterior probability of reductionpp = 1.00).The crudeoverall SHHevent-
rate in post-CSII vs pre-CSII person-timewas also lower: 17.8 events (95%CI 15.8, 19.9) per 1000 person-years post-exposure vs 25.8
(23.5,28.3)pre-exposure; rate ratio fromBayesianmixedmodels adjusting forpre-exposure trend:0.67 (95%CrI0.45,1.01;pp = 0.97).
Conclusions/interpretation CSII therapy was associated with marked falls in HbA1c especially in those with high baseline
HbA1c. CSII was independently associated with reduced DKA and SHH rates. CSII appears to be an effective option for intensive
insulin therapy in people with diabetes for improving suboptimal glycaemic control.
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CGM Continuous glucose monitoring
CrI Credible interval
CSII Continuous subcutaneous insulin infusion
DKA Diabetic ketoacidosis
MDI Multiple daily injections
NHS National Health Service
NICE National Institute for Health and Care
Excellence
pp Posterior probability
SCI-Diabetes Scottish Care Information-Diabetes
SHH Severe hospitalised hypoglycaemia
SIMD Scottish Index of Multiple Deprivation
Introduction
As continuous subcutaneous insulin infusion (CSII) usage
to aid diabetes management becomes more widespread,
there is still uncertainty regarding its effectiveness and
safety. RCTs reported small improvements in HbA1c
post-CSII initiation; before/after studies suggested larger
effects [1]. Several studies reported a reduction in severe
hypoglycaemia rates [1–3]. The effect of CSII on diabetic
ketoacidosis (DKA) is unclear as studies conflict in direc-
tion of effect reported [2–4].
Criteria for CSII initiation differ across countries [5]. CSII
therapy initiation in Scotland follows criteria set by the National
Institute for Health and Care Excellence (NICE) guidelines [6],
Scottish Government policy and individual National Health
Service (NHS) health board budget allocation decisions. A
recent study [7] examined the effect of CSII therapy on
HbA1c among people with type 1 diabetes in the Scottish health
board Lothian and found a significant decrease in HbA1c
following CSII initiation, particularly among those with subop-
timal glycaemic control. In this paper, we widen the scope of
that analysis by focusing on CSII therapy initiation in people
with type 1 diabetes throughout Scotland.
Our aim was to: (1) describe the current prevalence of ever-
CSII use; and (2) assess the effect of CSII therapy on
glycaemic control as measured by HbA1c, DKA and severe
hospitalised hypoglycaemia (SHH). We furthermore explored
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differences in CSII therapy effect across baseline HbA1c
bands and sociodemographic strata (age band at CSII initia-
tion, sex, area-level deprivation).
Methods
Ethics permissionData and data linkage were originally set up
with approval from the Scottish A Research Ethics Committee
(ref 11/AL/0225), Caldicott Guardians and the Privacy
Advisory Committee (PAC - ref. 33/11), now running with
approval from the Public Benefit and Privacy Panel for Health
and Social Care (PBPP - reference 1617-0147).
Data sources We used anonymised data from the Scottish
Care Information – Diabetes Collaboration database (SCI-
Diabetes), which holds extensive electronic healthcare records
of >99% of people with diabetes in Scotland, both adults and
children, since 2004. SCI-Diabetes covers extensive clinical
and prescription information including CSII start dates. These
data are linked to hospital admissions records and mortality
data from the Information Services Division (ISD) of NHS
Scotland and the National Records of Scotland. SCI-
Diabetes and associated linkage have previously been
described [8, 9].
Study population Among those alive and observable with
type 1 diabetes in SCI-Diabetes at any time from 2004 to
2019, we analysed glycaemic outcomes among those who
initiated CSII therapy before June 2019. Type of diabetes
was assessed from our validated algorithm [10]. Individuals
contributed person-time from the latest of: 1 January 2004,
first observability date (based on prescribing, hospital admis-
sion or clinical measurements) or date of diabetes diagnosis.
Person-time was censored at the earliest of: 12 December
2019 (administrative censoring), date of death, last date of
observability, first stop date of CSII (if no restart within a
year). Person-time was additionally censored when starting
flash monitoring or continuous glucose monitoring (CGM)
device after CSII to isolate the effect of CSII initiation from
that of other technologies (see electronic supplementary mate-
rial [ESM] Methods).
Exposure, outcomes and covariates Exposure of interest is
CSII therapy. Since CSII users in Scotland are selected based
on criteria that are not measurable in our data (e.g. motivation,
perceived ability to use a pump), we chose to conduct analyses
within CSII users. Glycaemic outcomes were compared
among CSII users before and after CSII initiation, using data
up to a maximum of 5 years prior to initiation. We used a 1:1
non-user control group, matched by age, sex and diabetes
duration (ESM Methods) to check for any trend occurring in
HbA1c among non-users in similar calendar time, and to
inform results obtained in adolescents given the deterioration
in glycaemic control in this age group [2, 11].
We defined DKA and SHH as any hospital admission or
death involving the ICD-10 (http:/ /apps.who.int/
classifications/icd10/browse/2016/en) codes detailed in ESM
Methods. Each unique hospital admission was considered as
an event. Person-time for DKA/SHH analyses was censored at
the last date of available data for hospital admissions: 30 April
2019.
Demographic and clinical information were obtained from
SCI-Diabetes. For clinical covariates, baseline values were
defined as median value over the 2 years prior to device initi-
ation for continuous variables or the most clinically severe
status over this time-window for categorical variables. We
used Scottish Index of Multiple Deprivation (SIMD) quintiles
as a measure of area-level deprivation, quintile (Q)1 being the
most deprived. Age at CSII initiation (years) was categorised
into six age bands: <13, ≥13–≤18, ≥19–≤24, ≥25–≤44,
≥45–≤64 and >64; and baseline HbA1c levels (mmol/mol) into
five groups, representative of different glycaemic control
levels: <54 (7.1%), ≥54–≤68 (8.4%), ≥69–≤74 (8.5–8.9%),
≥75–≤84 (9.0–9.8%) and >84.
Statistical analysis All analyses were conducted using R
version 3.6.0–64 bit [12] at significance level p = 0.05.
Missing data were not imputed.
We presented the crude prevalence of ever-CSII users over-
all and stratified by baseline variable. In order to study the
effect of CSII on HbA1c, we divided observation time into
blocks of 1 year periods before and after CSII initiation,
centred on the date of CSII initiation [7], and compared the
median HbA1c value of each individual in each time-block.
HbA1c levels and absolute within-person differences with
respect to baseline were described before and after CSII initi-
ation, overall and stratified by age, baseline HbA1c, sex,
SIMD and prior flash monitoring/CGM use. Significance of
within-person differences were assessed at each time point
after CSII initiation, using a one-sided Wilcoxon signed-
rank test; p values were adjusted for multiple comparison
using Bonferroni’s correction.
Crude pre-/post-exposure changes can under/overestimate
an intervention’s effect when there is a pre-intervention trend
in the outcome which is not taken into account. Log-
transformed HbA1c was modelled using linear mixed models
[13] to assess whether changes were similar and statistically
significant when accounting for pre-exposure trajectory [14].
CSII initiation in Scotland is a diffuse intervention. It is typi-
cally preceded by more frequent clinical encounters and atten-
dance at a structured education programme, such as Dose
Adjustment For Normal Eating (DAFNE), in the 2 years prior
to initiation. In modelling the impact of CSII, we wished to
ensure that any within-person trend over calendar time unre-
lated to CSII could be accounted for in the analysis. In order to
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evaluate this trend, theHbA1cmeasurementswithin the 2 years
prior to CSII initiation were excluded since they are related to
CSII (see ESM Methods for more details).
Therefore the models estimated the ‘full package’ effect of
CSII plus related prior interventions in the 2 year run-up to
CSII as they reflect change in HbA1c from before the package
started to after it was fully implemented. Models were fitted
using R package nlme version 3.1–143 [15]. Differential effect
of CSII by sociodemographic variable was tested using inter-
action terms (ESM Methods). Where significant, stratified
model results were presented.
Due to the sparse nature of DKA/SHH events, we
described the crude event-rate before and after CSII, by divid-
ing the number of events observed by the total number of
person-years under observation pre- or post-CSII exposure.
To account for repeated occurrence of events within individ-
uals and the background pre-package time-trend, we used
generalised linear mixed models with a Poisson likelihood
with a random intercept, excluding the 2 years prior to initia-
tion. CSII exposure was included as a binary, time-varying
covariate (non-exposed/exposed). All models were adjusted
for sex, age and diabetes duration at CSII initiation, baseline
HbA1c and pre-package time-trend. Classical likelihood infer-
ence for this model relies on approximations of intractable
integrals, therefore we used a Bayesian approach [16]. We
presented the back-transformed posterior mean (rate ratio)
and associated 95% credible intervals (CrI), alongside the
posterior probability (pp) of the β coefficient associated to
CSII exposure being positive or negative in order to quantify
the uncertainty around the direction of the effect [17]. Models
were implemented using R package rstan version 2.19.3 (see
ESM Methods for more details).
Results
Prevalence A total of 4941 people ever used CSII between
2004 and the end of 2019.The crude prevalence of ever-CSII
users has increased over the past decade from 0.1% in 2004 to
15.1% in 2019. Disparities in CSII usage by the end of 2019
were observed across sociodemographic strata (ESM Fig. 1).
Prevalence of ever-CSII users was highest in younger age
bands and decreased with age (48.1% in the under 13 age band
vs 4.3% in those aged 65 years or older), higher in female
(19.9%) vs male participants (11.3%) and twice as high
among those living in the least vs the most deprived areas
(19.6% in SIMD Q5 vs 10.4% in Q1).
Baseline cohort characteristics We analysed glycaemic
outcomes in 4684 CSII users who initiated CSII before
June 2019. Their baseline characteristics are described in
Table 1, alongside those of the non-user sample. Their median
overall observation time was 12.4 years; median post-
exposure follow-up time was 3.6 years; and 3108 individuals
started using flash monitoring/CGM after starting CSII.
HbA1c levels HbA1c decreased after CSII initiation (ESM
Fig.2) from median 66.0 mmol/mol (IQR 58.0, 74.0) (8.2%
[IQR 7.5, 8.9]) in the year before initiation to 60.0 mmol/l
(54.0, 67.0) (7.6% [7.1, 8.3]) during the first year of CSII
exposure and 63.0 (56.0, 71.0) (7.9% [7.3, 8.6]) after ≥5 years.
HbA1c levels started decreasing around 2 years prior to CSII
initiation, and levels were stable in the preceding years.
Crude within-person differences in HbA1c levels with
respect to baseline HbA1c are illustrated in Fig. 1 overall and
stratified by age at CSII initiation, sex, SIMD quintile and
baseline HbA1c. At an individual level, there was a reduction
in HbA1c levels post-CSII initiation sustained through time
(ESM Table 1): median −5.5 mmol/mol (IQR −12.0, 0.0)
(−0.5% [IQR −1.1, 0.0]) (p < 0.01) within the first year post-
exposure and −5.0 mmol/mol (−12.5, 2.8) (−0.5% [−1.1, 0.3])
(p < 0.01) for ≥5 years. Mixed-model results showed no time-
trend trajectory of HbA1c prior to CSII-package initiation.
CSII initiation was associated with a significant and sustained
long-term reduction in HbA1c levels compared with pre-
package levels (Table 2). The estimated fold-change was
0.88 overall. For someone with pre-package HbA1c levels of
69 mmol/mol (8.5%), this would correspond to a change of
around −8 mmol/mol (−0.7%).
Within-person HbA1c remained stable in the calendar time
following pump initiation in the non-user group, with a
within-person change of 0.0 mmol/mol (IQR −6.0, 5.5)
(0.0% [−0.5, 0.5]) in year 1 to −1.0 mmol/mol (−10.0, 9.0)
(−0.1% [−0.9, 0.8]) at ≥5 years (ESM Fig. 3).
CSII exposure effect varied significantly across baseline
HbA1c, age and sex, and prior flash monitoring/CGM use
(pinteraction<0.01 for all), but not across SIMD (pinteraction = 0.25).
Reductions in HbA1c from baseline were observed in all
bands ≥54 mmol/mol (7.1%) (Fig. 1, ESM Table 1), whereas
HbA1c levels increased slightly in the <54 mmol/mol band.
Reductions were significant and sustained through time, with
the greatest fall corresponding to the highest baseline HbA1c
bands: −21.0 mmol/mol (IQR −30.0, −11.0) (−1.9% [IQR
−2.7, −1.0]) (p < 0.01) in the first year post-exposure and
−19.0 mmol/mol (−27.6, −6.5) (−1.7% [−2.5, −0.6]) at
≥5 years in those with baseline HbA1c >84 mmol/mol
(9.8%) (p < 0.01). Results from the mixed models were simi-
lar (Table 2), with an estimated 0.8-fold-change sustained
through time in this group.
Within-person reductions in HbA1c were slightly higher in
female than male participants (ESM Tables 2, 3).
Across age, within-person HbA1c reductions were
highest among those aged 19–24. Significant reductions
were observed in all age bands and sustained through
time except in the 13–18 years group. In these adoles-
cents, after an initial decrease, there was no significant
1323Diabetologia  (2021) 64:1320–1331
difference from baseline beyond the second year. Model
estimates showed marginally higher values compared
with the expected pre-package HbA1c trajectory (ESM
Tables 4, 5). When compared with the matched controls
(ESM Fig. 4), HbA1c was lower in the adolescent group
in users both before and after CSII initiation. In non-
users, HbA1c rose from baseline levels until 3 years post-index:
median within-person change from baseline 5.0 mmol/mol
(IQR −6.0, 16.5) (0.5% [IQR 0.5, 1.5]) vs −0.0 mmol/mol
(−8.4, 8.0) (0.0% [−0.8, 0.7]) in non-users vs users respec-
tively (p < 0.01). Levels returned close to baseline in
subsequent years.
Within-person reductions in HbA1c did not vary across
SIMD (ESM Table 6). They were slightly higher in those with
prior flash monitoring/CGM use (ESM Tables 7, 8).
DKA and SHH events Overall, 1187 DKA events were
observed over 17,479.8 person-years prior to CSII initi-
ation, and 827 DKA events over 16,675.0 person-years
after initiation. The crude DKA rate increased prior to
package initiation and started decreasing thereafter
(ESM Fig. 5, ESM Table 9).
The crude DKA event-rate was significantly lower in CSII-
exposed person-time than in non-exposed person-time: 49.6
Table 1 Baseline characteristics of CSII users and matched non-users for analyses of glycaemic outcomes
CSII users (N=4684) Matched non-users (N=4141)
Variable n (%) or median (IQR) Missingness (%) n (%) or median (IQR) Missingness (%)
Sex, female 2749 (58.7) 0.0 2438 (58.9) 0.0
Age at initiation 27.5 (12.6, 41.3) 0.0 27.9 (13.5, 41.1) 0.0
Diabetes duration at initiation 11.4 (3.0, 22.9) 0.0 12.0 (3.3, 22.9) 0.0
HbA1c band at baseline 3.8 11.9
<54 mmol/mol (<7.1%) 529 (11.7) 377 (10.3)
54–68 mmol/mol (7.1–8.4%) 2117 (47.0) 1264 (34.7)
69–74 mmol/mol (8.5–8.9%) 713 (15.8) 563 (15.4)
75–84 mmol/mol (9.0–9.8%) 673 (14.9) 682 (18.7)
>84 mmol/mol (>9.8%) 474 (10.5) 761 (20.9)
n HbA1c measurements per individual 20.0 (14.0, 28.0) 0.0 25.0 (15.0, 36.0) 0.0
BMI, kg/m2 23.7 (19.4, 27.3) 5.8 23.9 (19.9, 27.9) 14.7
Triacylglycerols, mmol/l 1.0 (0.8, 1.4) 47.0 1.1 (0.8, 1.6) 51.2
Total cholesterol, mmol/l 4.6 (4.0, 5.2) 34.3 4.7 (4.1, 5.3) 40.0
HDL-cholesterol, mmol/l 1.5 (1.3, 1.8) 40.6 1.5 (1.2, 1.8) 46.4
LDL-cholesterol, mmol/l 2.5 (2.0, 3.0) 63.3 2.5 (2.0, 3.0) 67.6
Systolic BP, mmHg 123.5 (114.0, 133.0) 22.0 122.0 (113.0, 132.0) 25.8
Diastolic BP, mmHg 73.0 (67.5, 79.5) 22.0 73.0 (67.0, 79.0) 24.8
CKD-EPI eGFR, ml min−1 [1.73 m]−2 29.9 35.1
<15 15 (0.5) 32 (1.2)
15–30 18 (0.5) 17 (0.6)
30–60 73 (2.2) 75 (2.8)
60–90 647 (19.7) 479 (17.8)
≥90 2531 (77.1) 2086 (77.6)
Albuminuric status: micro/macro albuminuria 618 (21.5) 38.5 541 (25.6) 49.0
SIMD quintile 7.9 8.1
Q1 (most deprived) 618 (14.3) 933 (24.5)
Q2 787 (18.2) 812 (21.3)
Q3 933 (21.6) 793 (20.8)
Q4 944 (21.9) 678 (17.8)
Q5 (least deprived) 1032 (23.9) 588 (15.5)
Ever prior DKA admission 1011 (22.0) 1.8 1072 (27.5) 5.7
Ever prior hypoglycaemia admission 497 (10.8) 1.8 387 (9.9) 5.7
Prior FM/CGM usage 389 (8.3) 0.0 – –
FM, flash monitoring
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events (95% CI 46.3, 53.1) per 1000 person-years vs 67.9
(64.1, 71.9).
The Bayesian mixed models confirmed the increasing
trend in DKA frequency prior to package initiation and
demonstrated that CSII exposure was associated with a reduc-
tion in DKA rate compared with the counterfactual: rate ratio
0.61 (95% CrI 0.47, 0.77), with pp of β < 0 (i.e. reduction) =
1.00 (ESM Table 10). Hence, we can be very confident that
there is a true association.
Crude DKA rates by CSII exposure status, stratified by
baseline HbA1c band, sex, age and SIMD are described in
Fig. 2.
Stratified by baseline HbA1c band, significant reductions in
DKA rates were observed post-exposure in the 54–68 mmol/
mol and ≥ 75 mmol/mol groups (ESM Table 11). Model
results were consistent with an association of CSII exposure
with a reduction in DKA rate when controlling for pre-
intervention trend in the 54–68 mmol/mol and the
>84 mmol/mol bands (ESM Table 12).
Crude DKA rates were higher in female than male partic-
ipants (ESM Table 13) but lower in exposed person-time in
both groups.Model results were similar, with CSII being asso-
ciated with a rate reduction in both groups (ESM Table 14).
Across age band, crude rates were lower in CSII-exposed
time, except in the 13–18 years and 45–64 years groups (Fig.
2, ESM Table 15). Model results were generally similar (ESM
Table 16). Data were too sparse in the 65 years and older
group to draw meaningful conclusions. DKA rates in the
13–18 years group were higher in non-users than users both
before and after pump start-date. The crude event-rate in non-
users increased from 157.5 (95% CI 139.9, 176.7) pre-index
to 244.4 (224.7, 265.4) in the post-index person-time, i.e. as
the adolescents get older (ESM Fig. 6). The post-/pre-index
increase was similar to that observed in pump users: crude rate
ratio 1.55 (95% CI 1.35, 1.79) in non-users vs rate ratio 1.43
(1.16, 1.77) in users.
Higher deprivation levels were associated with increased
crude DKA rates. Rates were lower in exposed vs unexposed
person-time, though the difference was not always significant
(Fig. 2, ESM Table 17). Model results were similar (ESM
Table 18).
Crude DKA rates were lower in CSII-exposed time in both
those with and without prior flash monitoring/CGM use.
Sample size was too low for meaningful inference in the prior
flash monitoring/CGM group (ESM Tables 19, 20).
Overall, 451 SHH events were observed in the unexposed
person-years, and 296 events in the exposed person-years. The
crude SHH rate increased in all years prior to CSII initiation.
The crude SHH event-rate was lower in CSII-exposed than
non-exposed person-time: 17.8 events per 1000 person-years
(95% CI 15.8, 19.9) vs 25.8 (23.5, 28.3). Model estimates
from the Bayesian mixed models were consistent with an
association of CSII with a reduction in SHH rates compared
with pre-package levels: rate ratio 0.67 (95% CrI 0.45, 1.01),
pp = 0.97 (ESM Table 21). Hence, we have good confidence
that there is a true association. Event numbers were too low to
perform stratified analyses.
Discussion
We investigated the current prevalence of CSII usage among
the Scottish population with type 1 diabetes. We studied the
association of CSII therapy with HbA1c levels, DKA and SHH
event-rates. Prevalence of CSII usage is relatively low, but
growing, and varies substantially across sociodemographic
strata. CSII therapy was associated with a reduction in
HbA1c, which was sustained through time for at least 5 years.
The greatest reductions were seen in those with the highest
baseline HbA1c levels. Effects of exposure did not vary across
SIMD quintiles (but CSII prevalence did), while sustained
reductions of varying magnitude were seen across sex and
age bands, apart from in adolescents. Comparisons with
adolescent non-users nonetheless suggested an improvement
with CSII in this group. CSII was associated with an overall
reduction in DKA rate but the magnitude and direction of
effect varied across sociodemographic strata. CSII was asso-
ciated with an overall reduction in SHH rate.
CSII therapy is generally not funded out-of-pocket in
Scotland. There has been a significant increase in CSII provi-
sion across the country in the last 8 years in line with a nation-
wide effort to support the availability of CSII. Variability of
usage across sociodemographic strata followed similar
patterns to other countries: van den Boom et al. [18] reported
higher usage within younger age bands in the Diabetes
Patienten Verlaufsdokumentation (DPV) cohort. The
National Diabetes Insulin Pump Audit [19] (England,
Wales) 2017–2018 reported a higher pump-use prevalence
in women and in those from less deprived areas. Findings
from a qualitative study by Scott et al. [20] highlighting higher
access barriers to intensive insulin regimen (including CSII
therapy) for people from lower socioeconomic groups are
reflected in our observation that CSII prevalence is lower
among the most deprived.
Within-person changes observed in our national study
following CSII initiation were comparable in direction and
magnitude to those reported regionally in NHS Lothian [7].
We found the CSII therapy package to be independently asso-
ciated with a significant fall in HbA1c. Magnitude and direc-
tion of estimated changes are similar to those reported in
before/after studies of patients switching from multiple daily
injections (MDI) to CSII in Pickup and Sutton’s meta-analysis
[1]: −0.72% (−7.9 mmol/mol). Our findings are in line with
those from other local-scale UK studies which reported
improvements in glycaemic control following CSII initiation
to be sustained at least up to 5 to 6 years [7, 21, 22]. While
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diabetes care in Scotland has improved in the past decade, the
stability of HbA1c in the matched non-user sample supports
conclusions that observed reductions among pump users are
associated with CSII-package and not explained by the secular
trend of HbA1c improvement.
In line with previous findings, those with the highest baseline
HbA1c benefited most from CSII. NHS Lothian reported a
−22.2 mmol/mol change in those starting with HbA1c ≥
85 mmol/mol and the meta-analysis showed a mean difference
(MDI vs CSII) greater than 16mmol/mol for those with baseline
HbA1c ≥ 80 mmol/mol [1, 23]. Hence, CSII helps individuals
transition from higher to lower complication-risk HbA1c groups.
The slight increase in HbA1c in those with baseline levels
<54 mmol/mol is unsurprising as it is likely that this group
would have been prescribed CSII to reduce hypoglycaemia.
Differences observed across sex strata were similar to
previous findings [7, 24].
Patterns in HbA1c among those starting a pump in their
teenage years were similar to those described by Johnson
et al. in their long-term paediatric CSII outcome study (median
age 11.5 years) [2]. In their study, after an initial decrease,
HbA1c started increasing but remained lower than levels of
matched control participants onMDI, and differences remained
significant for 7 years. Our study’s matched differences stopped
being significant after 4 years, likely due to our group including
older individuals, who, after adolescence, transition into a phase
of more stable glycaemic control, whereas participants in the
study by Johnson et al. were censored when they transitioned to
adult services. Related to this, the higher reductions among the
19–24 years age band are likely due to a combination of
glycaemic control tending to stabilise at lower levels beyond
adolescence, and CSII use.
Although the sample size was small, we found that CSII
was beneficial in those initiating CSII after prior flash
monitoring/CGM usage.
We found CSII to be associated with a reduced overall
DKA rate, whereas previous findings have been conflicting.
A meta-analysis [25] suggested that CSII was associated with
higher DKA rates in older studies (before 1993). Pickup and
Keen [26] noted that modifiable factors such as patient/
healthcare provider inexperience can increase the likelihood
of DKA around the beginning of CSII use, as ketosis occurs
rapidly following insulin interruption due to use of rapid-
acting insulin in CSII devices [4], but we found no increase
of crude DKA rates within the first year of usage.
More recent studies have been inconclusive. Some paedi-
atric studies reported decreases, and others reported increases
[2–4, 27]. Thomas et al. [28] identified CSII as a predictor of
DKA in adults from the FinnDiane cohort. Different follow-
up times, DKA definitions (e.g. pH/bicarbonate-based) and
cohort characteristics (adults/children) could partially explain
the differing findings between studies. This variability is
reflected within our study by the difference in the direction
of estimates across age bands, with rate increase in the 45–
64 years age band, for example.
The increase in risk of DKA with deprivation levels in
Scotland was highlighted by Govan et al. [29]. Shulman
et al. [30] reported worse outcomes in those from lower
Fig. 1 Crude within-person differences in HbA1c (mmol/mol) with
respect to individual median over the 2 years prior to CSII initiation, by
time from CSII initiation (years). (a) Overall, (b) stratified by age band at
CSII initiation, (c) sex, (d) SIMD quintile, (e) baseline HbA1c band and
(f) prior flash monitoring/CGM usage. Results for prior flash monitoring/
CGM usage are presented up to 2–3 years post-CSII initiation as n <20 in
subsequent years for prior flashmonitoring/CGM group. Data are median
(IQR). Abbreviations: aft., after; bef., before; yr/yrs. year/years
Table 2 Modelled estimates of the yearly fold-change in HbA1c in the pre-package time period, and of the fold-change in HbA1c following CSII
initiation, compared with pre-package levels, overall and stratified by baseline HbA1c band














Time effect, years 1.00 (0.99, 1.00) 0.97 (0.97, 0.98) 0.99 (0.99, 1.00) 1.00 (0.99, 1.00) 1.01 (1.00, 1.02) 1.01 (0.99, 1.02)
CSII exposure time (ref=no CSII usage)
0–1 year 0.88 (0.87, 0.89) 0.99 (0.95, 1.02) 0.91 (0.89, 0.92) 0.89 (0.86, 0.91) 0.82 (0.79, 0.84) 0.79 (0.76, 0.83)
1–2 years 0.90 (0.89, 0.91) 1.04 (0.99, 1.08) 0.93 (0.91, 0.95) 0.90 (0.87, 0.93) 0.82 (0.79, 0.85) 0.81 (0.76, 0.85)
2–3 years 0.91 (0.90, 0.93) 1.08 (1.02, 1.14) 0.95 (0.93, 0.97) 0.90 (0.87, 0.94) 0.82 (0.79, 0.86) 0.82 (0.76, 0.87)
3–4 years 0.92 (0.91, 0.94) 1.14 (1.08, 1.22) 0.96 (0.93, 0.98) 0.91 (0.87, 0.95) 0.82 (0.78, 0.86) 0.82 (0.76, 0.89)
4–5 years 0.93 (0.91, 0.95) 1.19 (1.11, 1.28) 0.96 (0.93, 0.99) 0.91 (0.86, 0.96) 0.81 (0.77, 0.86) 0.80 (0.73, 0.88)
5 or more years 0.94 (0.92, 0.97) 1.24 (1.14, 1.35) 0.98 (0.95, 1.02) 0.93 (0.88, 0.99) 0.80 (0.75, 0.85) 0.80 (0.72, 0.89)
Number of observations 23,509 2427 10,842 3963 3777 2500
Number of individuals 4099 487 1954 648 595 415
Data are estimates (95% CI)
Pre-package time period refers to 2 years prior to CSII initiation and earlier
Adjusted for sex, age and diabetes duration at CSII initiation, and baseline HbA1c
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socioeconomic status in a Canadian paediatric study of pump
users. However, our findings show that although DKA rates
remain higher in more vs less deprived areas in post-pump
person-time, they were generally lower in post- vs pre-pump
person-time. Where differences were not significant, rates did
not increase post-pump.
Since recurrent DKA is an exclusion criterion for pump
therapy in Scotland, our conclusions pertain to a group of
people with type 1 diabetes who have a lower pre-exposure
propensity to DKA and may not generalise to those with a
higher baseline DKA propensity. It is crucial to understand
the mechanisms behind the observed reduction in DKA.
Several studies [1–3] have shown an association of CSII
with a reduction in severe hypoglycaemia rate (a 4.34 rate-
reduction factor was reported by Pickup and Sutton [1]).
Crude SHH rates were lower in CSII-exposed vs non-exposed
person-time, and the modelled estimate was consistent with an
improvement in SHH following CSII-package. However, our
findings are not comparable to other studies, which captured
severe hypoglycaemia events requiring third-party assistance,
whereas our definitionwas limited to hospital admissions, miss-
ing any events treated in the community.
Strengths This is one of the largest real-world, contemporary,
nationwide assessments of the prevalence of CSII and its
effect on glycaemic outcomes, combining near-complete
capture of data on people with type 1 diabetes nationally, long
follow-up time and extensive analyses.
Limitations The main limitations of our study are the lack of
data in older people, incomplete capture of self-funded flash
monitoring use and non-capture of non-hospitalised severe
hypoglycaemia [31]. CSIIs can be prescribed for debilitating
hypoglycaemia in adults or children older than 12, as recom-
mended by NICE [6], but we could not evaluate
hypoglycaemia as an effectiveness outcome for CSII therapy.
In Scotland, eligibility for receiving CSII on the NHS has
evolved over time: from 2011 there was a major push to widen
provision, and the clinical and sociodemographic profile of
those receiving pumps has changed. However, the vast major-
ity of CSII initiation occurred since 2011, with most of our
data reflecting those initiating pump therapy in the period
2013–2017 and followed up to the present day (median start
date 5 December 2014 [IQR 16 June 2013, 27 February

























































































































































































Pump exposure status Unexposed Exposed
Fig. 2 Crude DKA event-rates, by CSII exposure status, stratified by (a) age band at CSII initiation, (b) sex, (c) SIMD quintile, (d) baseline HbA1c band,
(e) prior flash monitoring/CGM usage. Data are crude event rates (95% CI)
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and outcomes of those in receipt of CSII therapy which ismost
relevant to current effectiveness and safety estimation.
The majority of CSII users had their person-time censored
for start of flash monitoring/CGM. The person-time lost to
follow-up was relatively low and unlikely to affect the analy-
ses since the step-change in HbA1c occurs within the first year
post-CSII initiation.
Generalisability of findings to all people with type 1 diabe-
tes is limited by the allocation bias resulting from the selection
process for pump therapy.
Our HbA1c analyses are susceptible to regression to the
mean. However, the magnitude of pre–post change among
never-users indicates that only a small proportion of the
decrease observed in users following CSII initiation would
actually be attributable to this artefact. Finally, as with all
observational analyses, our estimates may be affected by
unmeasured confounding and measurement error, although
the self-controlled nature of some analyses eliminates time-
invariant confounding.
Conclusions Our study shows that CSII therapy is associated
with improvements in HbA1c, DKA and SHH among pump
users with type 1 diabetes in Scotland. The improvements asso-
ciated with CSII therapy suggest that a more widespread use of
pump therapy has the potential to reduce HbA1c levels andDKA
rates further. Our study highlights the importance of CSII tech-
nology reaching those with suboptimal glycaemic control and
those from most deprived areas. This latter group, with histori-
cally poorer glycaemic control [10], stands to benefit from CSII
usage, as we have not found evidence of CSII effects being
worse in people from more deprived areas (in contrast to their
CSII usage rates). Future research is needed to assess the effect
of SIMD on outcomes in specific subgroups. Generalisation of
our findings to all people with type 1 diabetes in Scotland is
limited by the specific eligibility criteria to CSII. Hence, it is
crucial to identify the determinants of good response to CSII to
optimise a targeted wider roll-out. Moreover, other outcomes
that we cannot directly quantify need to be considered, such as
improvement in quality of life and reduction in glucose variabil-
ity. Motivation is critical to successful CSII usage [23], and it
would be interesting to examine how outcomes differ in a
known-to-be-motivated group (pregnant women). Finally, future
research is warranted to examine how the rapid evolution of
technology (integrated pump-and-CGM systems with alarms
and/or suspension systems, hybrid/DIY closed loops) affects
DKA and severe hypoglycaemia rates.
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